Indian Journal of Pharmacy and Pharmacology 2020;7(2):130–135 Content available at: iponlinejournal.com Indian Journal of Pharmacy and Pharmacology Journal homepage: www.ipinnovative.com Original Research Article Efficacy of tiotropium bromide inhalation in COPD and bronchial asthma patients for a period of 14 weeks Ahmed Abdul Bari Hazari 1, * 1 Dept. of Pharmacology, Ayaan Institute of Medical Sciences, Ranga Reddy, Telangana, India ARTICLE INFO Article history: Received 15-04-2020 Accepted 09-05-2020 Available online 24-07-2020 Keywords: Bronchial asthma COPD FEV1 FVC FEV1/FVC ratio ABSTRACT Background: Chronic Obstructive Pulmonary Disease affects more than 15 million Americans, with the majority of the patients more than 50 years old with current or past smokers. Objective: To study the safety and efficacy of Tiotropium bromide inhalation in both COPD & Bronchial Asthma patients. Materials and Methods: The present study was conducted in patients with stable as well as exacerbated COPD and Br. Asthma at Shadan Hospital, Telangana. Results: Significant improvement in Forced expiratory volume with respect to baseline at the end of the 14 th week. The maximum mean response in FEV 1 improved by 0.221, (68.03%) when the compared value of baseline 0.13L (p-value < 0.001) significant improvement in Bronchial asthma but little less effective compared to COPD treatment group. The Forced expiratory volume (FEV 1 ), Forced vital capacity (FVC) and FEV 1 /FVC ratio were improved with respect to baseline. Conclusion: Tiotropium via dry powder inhaler result in 24 hr bronchodilation as well as consistent and sustained improvement for both the COPD and the Bronchial Asthma patients. © 2020 Published by Innovative Publication. This is an open access article under the CC BY-NC license (https://creativecommons.org/licenses/by-nc/4.0/) 1. Introduction Chronic Obstructive Pulmonary Disease is a potentially fatal, slowly progressive respiratory disease. In contrast to Bronchial Asthma, COPD is characterized by air flow obstruction that is not fully reversible. The signs and symptoms are chronic coughs, excessive mucous production, wheezing and shortness of breath after mild exertion. In practice, COPD tends to be under diagnosed and undertreated, for a number of reasons. However, the availability of detailed and practical guidelines from the Global Initiative for Chronic Obstructive Lung Disease will be useful for improving COPD care through primary care needs to respond by developing systems to ensure these guidelines are implemented in practice. * Corresponding author. E-mail address: drfarhanhazari@gmail.com (A. A. B. Hazari). Tiotropium bromide, long-acting, inhaled Anti choliner- gic bronchodilator, selectively inhibits the muscarinic recep- tors involved in mucous secretion and bronchoconstriction. Long term clinical trials have demonstrated the efficacy of Tiotropium in patients with COPD. 1,2 Tiotropium is well tolerated, with a safety profile comparable with that of a placebo. The parasympathetic nervous system plays an important role in autonomic control of airways and is believed to be largely responsible for resting the vagal tone in COPD. 3–5 Bronchial Asthma is a chronic inflammatory disorder of airways. It is characterized by airflow obstruction that is typically reversible and by airway hyper responsiveness to various stimuli. According to WHO, between 100 and 150 million people around the globe suffer from Bronchial Asthma and the number is rising. 6 Tiotropium bromide is a semisynthetic derivative with Anticholinergic properties specific for muscarinic receptors https://doi.org/10.18231/j.ijpp.2020.022 2393-9079/© 2020 Innovative Publication, All rights reserved. 130